Selinexor (XPOVIO) was approved by the FDA in 2019 to be used with dexamethasone for patients who had relapsed five types of myeloma treatment. The BOSTON study results published today in The Lancet show that selinexor, weekly bortezomib (Velcade) and low-dose dexamethasone is an effective combination for multiple myeloma patients who have received 1-3 lines of prior therapy.
The BOSTON study, performed at 123 sites in 21 countries, included 402 patients. Patients were split into two groups evaluating once-weekly selinexor in combination with once-weekly bortezomib (Velcade) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. This is the first trial to evaluate a once-weekly bortezomib schedule in relapsed multiple myeloma compared to a twice weekly comparator Vd arm.
Median progression free survival was 13.93 months with the selinexor/bortezomib/dex combination vs. 9.46 months with bortezomib/dex. Interestingly, peripheral neuropathy of grade 2 or higher was less frequent when selinexor was added (21%) compared to the doublet combination (34%). The mortality rate during the study was 24% in the selinexor/bortezomib/dex arm vs. 30% in the bortezomib/dex arm.
The FDA accepted a New Drug Application earlier this year for selinexor use in patients with only one prior line of therapy. These Phase III BOSTON study results paved the way for the FDA to set a march 19, 2021 date (based on the Prescription Drug User Fee Act, or PDUFA).
Additional clinical trials such as the STOMP trial are underway to examine selinexor with other standard myeloma therapies.
This once-weekly (all oral) option may be a new, effective and convenient treatment options for patients at earlier relapse.
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.